Applications of the MOTOR gene in the preparation of drugs for treating sepsis and related drugs

Drugs prepared using the MOTOR gene or its pharmaceutical derivatives reverse LPS tolerance in monocytes, regulate the immune function of sepsis patients, solve the problems of immunosuppression and secondary infection in sepsis patients in existing technologies, and prolong survival time.

CN116814623BActive Publication Date: 2026-11-10SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310773883.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-28
Publication Date
2026-11-10
Estimated Expiration
2043-06-28

AI Technical Summary

Technical Problem

Current technologies lack molecular drugs to regulate LPS tolerance in monocytes, leading to high risk of immunosuppression and secondary infection in sepsis patients, and reduced ability of monocytes to internalize and kill pathogens.

Method used

Using the MOTOR gene or its pharmaceutical derivatives, through peripheral blood release or exosomes, mononuclear cell LPS tolerance is reversed, and the innate and adaptive immune functions of sepsis patients are modulated, and the drugs are prepared into various pharmaceutically acceptable dosage forms such as tablets, capsules, and oral liquids.

Benefits of technology

It promotes the secretion of chemokines and the expression of pro-inflammatory cytokines by monocytes under bacterial infection, prevents secondary infection, and improves the survival time of sepsis patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116814623B_ABST
    Figure CN116814623B_ABST
Patent Text Reader

Abstract

This invention discloses the application of the hsa_circRNA gene MOTOR in the preparation of a drug for treating sepsis and the drug itself, belonging to the field of circRNA-encoded small peptides. Based on the gene sequence of hsa_circRNA_056558, a vector overexpressing hsa_circRNA_056558 was constructed via molecular cloning. This vector was transfected into cells, and exosomes produced by the cells were collected by ultracentrifugation. The exosomes contain MOTOR. MOTOR can enhance the function of monocytes and can be used for immunomodulatory therapy of sepsis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of gene technology for circRNA-encoded small peptides, and more specifically to the application of the MOTOR gene in the preparation of a drug for treating sepsis and the drug itself. Background Technology

[0002] Sepsis is a life-threatening organ dysfunction caused by a dysregulated response to infection, posing a significant threat to human health. A multicenter cross-sectional study in my country showed that sepsis patients account for approximately 20.6% of ICU admissions, with a 90-day mortality rate as high as 35.5%. Therefore, in-depth research into the pathogenesis of sepsis and the search for new therapeutic targets are not only a national and societal need for the prevention and control of major diseases, but also a major challenge for clinicians.

[0003] Immune imbalance is the fundamental mechanism of sepsis development. Although multi-organ damage caused by excessive inflammation is an important aspect of sepsis pathogenesis, the hyperinflammatory state of sepsis is often accompanied by long-term and persistent immunosuppression. Monocyte LPS tolerance is a key feature of immunosuppression in sepsis. LPS-tolerant monocytes have reduced ability to internalize and kill pathogens, and cannot respond effectively to secondary infections, increasing the risk of secondary infection in sepsis patients, which is the leading cause of death in sepsis patients. However, the exact mechanism of LPS tolerance in monocytes remains unclear, and there are currently no molecular drugs to regulate monocyte LPS tolerance, which is a core issue that urgently needs to be addressed. Summary of the Invention

[0004] To address the shortcomings of existing technologies, this invention proposes the application of the hsa_circRNA gene MOTOR in the preparation of drugs for treating sepsis. MOTOR reverses LPS tolerance in sepsis monocytes and prolongs the survival time of mice.

[0005] The objective of this invention can be achieved through the following technical solutions:

[0006] The first aspect of this application discloses the use of the MOTOR gene or a pharmaceutical derivative thereof in the preparation of a medicament for treating sepsis, wherein the nucleotide sequence of the MOTOR gene is shown in SEQ NO.1.

[0007] Furthermore, the drug is used in a dosage form suitable for releasing the MOTOR gene or a pharmaceutical derivative thereof in the user's peripheral blood.

[0008] This application also provides a drug comprising exosomes containing the MOTOR gene; the nucleotide sequence of the MOTOR gene is shown in SEQ NO.1.

[0009] By adding conventional excipients and following conventional processes, the drug of this invention can be formulated into various pharmaceutically acceptable dosage forms, such as tablets, capsules, oral liquids, lozenges, injections, ointments, granules, or various sustained-release preparations.

[0010] The carriers of the drugs of this invention are common types available in the pharmaceutical field, including: binders, lubricants, disintegrants, solubilizers, diluents, stabilizers, suspending agents, or matrices, etc.

[0011] Preferably, the dosage form is an injection.

[0012] The beneficial effects of this invention are:

[0013] The gene sequence of hsa_circRNA_056558 in this application can reverse LPS tolerance in monocytes during sepsis, promote the expression of chemokines, pro-inflammatory cytokines and antigen-presenting genes secreted by monocytes under bacterial infection, regulate the innate and adaptive immune functions of sepsis patients, prevent secondary infection, and improve survival time. Attached Figure Description

[0014] The invention will now be further described with reference to the accompanying drawings.

[0015] Figure 1 This is a schematic diagram of the small peptide structure of MOTOR located in the cytoplasm of this application;

[0016] Figure 2 This diagram illustrates how knocking down MOTOR inhibits the expression of inflammatory and chemokine factors in this application.

[0017] Figure 3 This is a diagram showing how overexpression of MOTOR promotes the expression of inflammatory factors and chemokines in this application;

[0018] Figure 4 This is a particle size analysis diagram of the Motor exosomes of this application. Detailed Implementation

[0019] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0020] In the description of this specification, references to terms such as "an embodiment," "example," "specific example," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, illustrative expressions of the above terms do not necessarily refer to the same embodiment or example.

[0021] This invention employs the following steps to verify the effect of MOTOR on LPS tolerance in monocytes during sepsis; for details, please refer to the appendix. Figure 1-4 ;

[0022] Example 1: MOTOR is a coding circRNA that can translate into a 137aa small peptide.

[0023] 1.1 MOTOR was identified as a circRNA by PCR and Sanger assays. Bioinformatics was used to predict MOTOR's coding ability, and Western blot and immunofluorescence techniques were used to verify MOTOR's coding ability and subcellular localization. It was found that MOTOR can translate into small peptides localized in the cytoplasm (see...). Figure 1 ).

[0024] 1.1.1 PCR and Sanger sequencing experiments

[0025] (1) RNA extraction:

[0026] a) Prepare the necessary reagents and consumables: Trizol; chloroform; isopropanol; DEPC water; RNase-free pipette tips of various sizes; 1.5 mL RNase-free EP tubing

[0027] b) The specific procedure is as follows: Collect human monocytes (THP1) and place them in EP tubes. Add 1 ml of Trizol to each EP tube and repeatedly pipette until no cell pellet is visible. Pre-cool the centrifuge to 4°C, add 0.2 ml of chloroform to each EP tube, vortex for 15 seconds, and incubate at room temperature for 5 minutes. Then set the centrifugation conditions to 12000 rcf and centrifuge for 15 minutes. After centrifugation, the mixture will separate into three layers: the upper layer is colorless aqueous RNA, and the middle and lower layers are organic phenol-chloroform layers. Carefully remove the EP tubes and vertically aspirate 0.4 ml of the supernatant. Add 0.5 ml of isopropanol, invert and mix 10 times, and let stand at room temperature for 10 minutes; set the centrifugation conditions to 12000 rcf for 10 minutes; then discard the supernatant, add 75% ethanol prepared with DEPC water to each EP tube, invert and mix; set the centrifugation conditions to 7500 rcf for 5 minutes, remove and discard the supernatant; briefly centrifuge for 15 seconds, discard the supernatant, and retain the RNA precipitate; then add 30 μl of DEPC water to dissolve the precipitate and measure the RNA concentration using a spectrophotometer, and then adjust the concentration to 1 ng / μl with DEPC water.

[0028] (2) Reverse transcription PCR: using a reverse transcription kit (PrimeScript) TM The RT reagent kit with gDNAEraser (TAKARA, RR047A) was used to perform reverse transcription PCR on 500 ng of RNA.

[0029] (3) PCR: Dilute the cDNA obtained from the previous reverse transcription step three times with RNase-free water and prepare it according to the following system:

[0030] 2×PCR buffer for KODFX 25.0μl Primer1 (10μM) 0.4μl Primer2 (10μM) 0.4μl 2mMdNTPs 10.0μl TemplateDNA / cDNA 2.0μl KODFX (1.0U / μl) 1.0μl ddH2O To 20.0μl

[0031] The PCR primer sequences are as follows:

[0032] MOTOR-F GGCAGAAGTGAAAGATACAACC MOTOR-R ACTCCTCCTGCCAGATTACAGAT

[0033] After configuring the PCR system, the reaction was performed using a Bio-Rad PCR instrument. The PCR products were then sent to Shanghai Sangon Biotech for Sanger sequencing (see attached). Figure 1 ).

[0034] 1.1.2 Western Blot Experiment

[0035] (1) Protein extraction experiment:

[0036] a) Prepare the necessary reagents and consumables: RIPA protein lysis buffer; Cocktail protease inhibitor; sterilized 1.5ml EP tubes.

[0037] b) The specific steps are as follows: Transfect the FLAG-MOTOR plasmid into cells in a 12-well plate, add 100 μl of RIPA and a cocktail inhibitor, and incubate on ice for 10 min; then set the centrifugation conditions to 12000 rpm, 4℃, and 20 min; carefully aspirate the supernatant, which is the desired protein. Add 5x loading buffer and heat at 100℃ for 5 min.

[0038] (2) Immunoblotting experiment

[0039] a) Gel preparation: Prepare 12% SDS-PAGE gel using the 12% PAGE Gel Rapid Preparation Kit (Bio-rad; 64484826):

[0040] 1. Take 3 ml of Resolver A and Resolver B solutions respectively, add 3 μl of TEMED and 30 μl of 10% AP. Vortex to mix, and pour into the gel casting glass plate, ensuring the distance between the liquid surface and the upper edge of the short glass plate is 0.5 cm longer than the comb teeth; take 1 ml of Stack A and Resolver B solutions respectively, add 2 μl of TEMED and 10 μl of 10% AP. Vortex to mix, pour into the gel casting glass plate, and insert the comb teeth;

[0041] 2. After waiting 30 minutes for the top layer of gel to solidify, remove the comb teeth and it is ready for electrophoresis.

[0042] b) Electrophoresis:

[0043] 1. Place the solidified gel plate into the electrophoresis tank and add sufficient 1xRunningbuffer;

[0044] 2. Vortex the cooked protein sample to mix well, and after a brief separation, add 5 μL of molecular weight protein standard sample and 15 μL of protein sample to the spotting well respectively;

[0045] 3. Set the electrophoresis conditions: constant voltage 200V, 45 minutes;

[0046] c) Transfer:

[0047] 1. Cut PVDF film of the corresponding size according to the target strip and irrigate the film with methanol for 10 minutes;

[0048] 2. After electrophoresis, use a gel opener to pry open the glass plate and cut off the separating gel, placing it in the transfer buffer;

[0049] 3. Use the sandwich method: positive electrode (white) - sponge pad - three layers of filter paper - PVDF membrane - separating gel - three layers of filter paper - sponge pad - negative electrode (black). The entire operation is carried out in the transfer solution, gently rolling each layer to remove air bubbles.

[0050] 4. Set the transfer conditions: constant current 300mA, 60 minutes, add 1x transfer solution; since the transfer process generates heat, the transfer tank needs to be placed in a low-temperature environment.

[0051] d) Closed:

[0052] 1. Place the membrane in the pre-prepared blocking solution (2.5g bovine serum albumin + 50ml 1xTBST) and block it on a shaker at room temperature for 1 hour.

[0053] f) Immune response:

[0054] 1. Gently wash away the surface sealing solution using 1xTBST;

[0055] 2. Prepare primary antibody (5 μl FLAG primary antibody + 10 ml 1xTBST), add it to the incubation box, and gently shake the membrane in the box with the shaker. Incubate overnight at 4°C.

[0056] 3. Recover the primary antibody, wash the membrane three times with 1xTBST for 7 minutes each time, then incubate with the secondary antibody at room temperature for 60 minutes. Recover the secondary antibody, wash the membrane three times with 1xTBST for 7 minutes each time. Immerse the membrane in 1xTBST solution for the next step.

[0057] g) Colorimetric reaction

[0058] 1. Open the Eblot ultra-sensitive fully automated luminescence imaging analysis system;

[0059] 2. Mix the luminescent liquid A and liquid B in a 1:1 ratio until homogeneous, then pipette the mixture evenly onto the membrane and expose it for photographs.

[0060] The results showed that Flag-MOTOR could be detected, indicating that MOTOR can encode proteins.

[0061] 1.1.3 Immunofluorescence staining

[0062] (1) Primary antibody incubation

[0063] Flag-MOTORTHP1 cells were collected, fixed with 4% PFA at room temperature for 1 h, washed three times with PBS for 5 min each time, blocked with blocking medium (1% fetal bovine serum + 0.5% Tritonx-100) at room temperature for 1 h, and then Flag antibody diluted 1:200 with PBS was added and incubated overnight at 4°C.

[0064] (2) Secondary antibody incubation

[0065] Rinse the slide three times with PBS for 5 minutes each time; then dilute the corresponding secondary antibody with PBS at a ratio of 1:400 (and DAPI at a ratio of 1:1000), incubate at room temperature for 1 hour, rinse three times with PBS for 5 minutes each time, and mount with nail polish; acquire images using a confocal microscope.

[0066] The results showed that Flag-MOTOR is mainly located in the cytoplasm.

[0067] Example 2: Knocking down MOTOR inhibits the release of chemokines and pro-inflammatory cytokines from monocytes stimulated by LPS.

[0068] 2.1 Human monocytes (THP1) were cultured in vitro. siRNA specifically targeting MOTOR circRNA was ordered. The MOTOR-targeting siRNA and control siRNA were transfected into the cells using the NEON electroporation system. 1 μg / ml LPS was added 24 h after transfection, and cells were harvested 24 h after LPS treatment. The expression of cytokines and antigen presentation-related factors was detected by next-generation sequencing and qPCR. It was found that knockdown of MOTOR significantly inhibited their expression (see...). Figure 2 ).

[0069] 2.1.1 Next-generation sequencing and analysis

[0070] (1) Collect cells, centrifuge at 500 rcf for 5 min at room temperature, discard the culture medium, wash the cell pellet with PBS once, and add 1 ml Trizol.

[0071] (2) Trizol samples containing cells were placed in liquid nitrogen for 30 seconds and then sent to the company for next-generation sequencing on dry ice.

[0072] (3) After the company returns the sequencing data, analyze the expression of chemokines and pro-inflammatory factors, normalize them using FPKM and z-score algorithms, and create a heatmap to reflect the expression differences of related genes.

[0073] 2.1.2 qPCR

[0074] (1) Prepare the qPCR system as follows:

[0075] cDNA 2μL SYBR 5μL F-primer 0.2μL R-primer 0.2μL <![CDATA[ddH2O]]> 2.6μL Total 10μL

[0076] After performing qPCR detection, the CT values ​​obtained were analyzed, and the expression levels of the corresponding chemokines and pro-inflammatory factors were calculated.

[0077] The results showed that siRNA knockdown of MOTOR significantly reduced the expression levels of chemokines and pro-inflammatory factors in both next-generation sequencing and qPCR assays.

[0078] Example 3: Overexpression of MOTOR promotes the release of chemokines and pro-inflammatory cytokines from monocytes stimulated by LPS.

[0079] MOTOR was overexpressed in monocytes via lentiviral infection. The effect of MOTOR overexpression on cytokine release from monocytes under LPS stimulation was detected by qPCR. The results showed that MOTOR overexpression promoted the monocyte response to LPS (see...). Figure 3 ).

[0080] 3.1 Lentiviral Packaging and Purification

[0081] (1) HEK293T cells were co-transfected with vsvg, rev, gag and Flag-MOTOR plasmids; the nucleic acid sequence of the MOTOR plasmid encoding the biological factor MOTOR is shown in SEQ NO.1.

[0082] (2) 48 hours after transfection, collect the supernatant from the culture dish and replace it with fresh DMEM medium containing 1% FBS. Collect the supernatant a second time after 96 hours.

[0083] (3) Add 1 / 5 of the volume of virus concentrate, mix well, and let stand overnight at 4°C.

[0084] (4) Centrifuge the supernatant containing the virus concentrate at 4°C, 11000 rcf for 30 minutes. Discard the supernatant, and the precipitate is the virus particles. Resuspend the virus in 1.5 ml of DMEM medium and store at -80°C.

[0085] 3.2 Lentiviral infection

[0086] (1) Take 2x10 5 THP1 cells were placed in 12-well plates, 500 μl of virus solution was added, and the plates were incubated in a cell culture incubator.

[0087] (2) One week after infection, puromycin was added for screening. The cells that were screened were the cells that overexpressed MOTOR (MOTOR OE).

[0088] 3.3 Detection of chemokines and pro-inflammatory cytokines

[0089] (1) Stimulate MOTOR OE and control cells with 1 μg / ml LPS, collect cells by centrifugation after 24 h, and extract RNA.

[0090] (2) Detection of the expression of chemokines and pro-inflammatory cytokines using qPCR

[0091] The results showed that overexpression of MOTOR significantly increased the expression of chemokines and pro-inflammatory cytokines.

[0092] Example 4: Motor-containing exosomes prolong the survival time of septic mice

[0093] Exosomes overexpressing MOTOR were collected and injected into septic mice via tail vein injection, which significantly prolonged the survival time of the septic mice.

[0094] 4.1 Extraction of exosomes containing MOTOR

[0095] (1) Collect the supernatant of 293T cells and 293T cells overexpressing MOTOR, centrifuge at 500g for 5min, discard the precipitate and keep the supernatant; centrifuge at 2000g for 5min, discard the precipitate and keep the supernatant; centrifuge at 12000g for 30min, discard the precipitate and keep the supernatant; centrifuge at 200000g for 90min, discard the supernatant and keep the precipitate; resuspend the precipitate with PBS, centrifuge at 200000g for 90min, discard the supernatant and keep the precipitate, and resuspend with 200ul PBS.

[0096] (2) Perform negative staining and electron microscopy.

[0097] 4.2 Exosomes containing MOTOR and control exosomes were injected into septic mice, and the survival time of the mice was observed.

[0098] 4.2.1 Establishment of a mouse model of sepsis using the cecum ligation and puncture (CLP) method

[0099] (1) C57BL / 6 wild-type mice (male, 6-7 weeks, 20-29g) were anesthetized. A 0.5cm incision was made about 1cm below the xiphoid process on the midline of the abdomen. The cecum was explored and slowly pulled out of the abdominal cavity. The cecum was ligated twice in the midline of the ligation segment. After confirming that there was no obvious bleeding, the cecum was returned to the abdomen. Postoperatively, 1ml of 0.9% saline was administered subcutaneously for anti-shock treatment. The mice were allowed to eat and drink freely after the operation and the room temperature was kept constant.

[0100] (2) Dilute the exosomes with PBS to a concentration of 1 x 10⁻⁶ ppm per 200 μl. 9 Two exosomes were injected into mice via tail vein at 24, 48 and 72 h after the sepsis model was established.

[0101] (3) The time of the first injection of exosomes was recorded as 0h, and the survival status of mice was observed and recorded every 24h.

[0102] The results showed that injection of exosomes containing MOTOR significantly prolonged the survival time of septic mice.

[0103] Figure 1 A. A schematic diagram of MOTOR and first-generation sequencing of junction site; B. Bioinformatics prediction of RNA coding ability, CDR1as and HOTAIR are classic circRNAs and lncRNAs that have been shown to function as RNA but do not encode proteins, and Actin is a known protein-coding gene; C. Western blot shows that Flag-MOTOR can be detected by Flag antibody; D. Indicates Flag-MOTOR immunofluorescence. Figure 2 Knocking down MOTOR inhibits the expression of chemokines and antigen presentation-related molecules. RNA-seq (A) and qPCR (B) show the expression of chemokines and cell antigen presentation-related molecules after knocking down MOTOR.

[0104] Figure 3 A. The expression level of MOTOR after overexpression of MOTOR and its role in the analysis of chemokines in LPS-stimulated monocytes. B. The mRNA levels of CCL2, CCL3 and CCL4 after LPS stimulation following MOTOR overexpression, as detected by qRT-PCR.

[0105] Figure 4 Motor-containing exosomes promoted the survival time of septic mice. A and B. NTA and electron microscopy analysis showed that exosomes were extracted by this method; C. Injection of motor-containing exosomes into mice via tail vein injection significantly increased the survival time of septic mice.

[0106] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the claimed invention.

Claims

1. The application of the MOTOR gene in the preparation of drugs for treating sepsis, characterized in that, The nucleotide sequence of the MOTOR gene is shown in SEQ NO.

1.

2. The application according to claim 1, characterized in that, The drug is used in a formulation suitable for releasing the MOTOR gene in the user's peripheral blood.

3. The application according to claim 2, characterized in that, The dosage forms include tablets, capsules, oral liquids, lozenges, injections, ointments, and granules.

4. The application according to claim 3, characterized in that, The dosage form is an injection.

5. A drug for the prevention or treatment of sepsis, characterized in that, The drug comprises exosomes containing the MOTOR gene; the nucleotide sequence of the MOTOR gene is shown in SEQ NO.

1.

6. The drug according to claim 5, wherein the dosage form of the drug is tablet, capsule, oral liquid, lozenge, injection, ointment, or granule.

7. The drug according to claim 6, characterized in that, The dosage form is an injection.